Skip to main content
. 2020 Sep 17;5(18):e137646. doi: 10.1172/jci.insight.137646

Figure 4. Quantitative measurements of amelioration of ventriculomegaly in hydrocephalic Tmem67–/– rats by treatment with a TRPV4 antagonist, RN 1734.

Figure 4

(A–C) WT (Tmem67+/+), heterozygous (Tmem67+/–), and homozygous/hydrocephalic (Tmem67–/–) ventricular volumes (mm3) at P7 and P15 in animals treated with either vehicle or RN 1734. (D) Change in ventricular volume (delta, Δ) from P7 to P15 for each genotype and treatment group. WT, vehicle (n = 11); WT, RN 1734 (n = 12); Het, vehicle (n = 14); Het, RN 1734 (n = 11); Hom, vehicle (n = 11); Hom, RN 1734 (n = 12). All data shown are the mean ± SEM for each group. Significance values were determined by 2-way ANOVA test in Prism using genotype and treatment as variables. Het, heterozygous; Hom, homozygous/hydrocephalic; vehicle = DMSO/saline daily i.p. injection; RN 1734, RN 1734, TRPV4 antagonist; 4 mg/kg BW i.p. daily injection.